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52have been limited (5–9), even
though PAD affects over 7
million Americans (10) and
disproportionately affects those
of lower socioeconomic status
(SES) (11,12). Equitable accessto inexpensive, guideline-recommended secondary preven-
tive therapies has the potential to improve cardiovascular
outcomes in this vulnerable population (13–17), but whether
treatment rates differ across income groups remains
unknown. Given that PAD is associated with increased
cardiovascular risk and mortality (18–22), illuminating
current practice patterns by SES for evidence-based
secondary preventive strategies is particularly important in
deﬁning opportunities to better improve care.
Accordingly, we examined PAD treatment rates by
SES within the American College of Cardiology’s (ACC)
National Cardiovascular Disease Registry (NCDR) PIN-
NACLE Registry, which prospectively captures information
on the clinical care of outpatients, including the use of
guideline-recommended secondary preventive therapies.
Given the potential variability in care across clinics, we
explicitly sought to examine both the variations in secondary
preventive treatment of PAD by SES and whether treatment
differences by SES were explained at the site level, with the
hope that our ﬁndings would not only identify potential
disparities by income but also deﬁne targets for future
interventions to reduce disparities in PAD care.Methods
Study population. The PINNACLE Registry was launched
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; accepted April 17, 2013.patients in the United States (23,24). Among participating
practices, patient data were collected at the point of care
for a variety of cardiovascular conditions, including coro-
nary artery disease, heart failure, atrial ﬁbrillation, and
PAD. Participation in this quality-improvement initiative is
voluntary.
For the purposes of this study, we identiﬁed 66,282
patients with a diagnosis of PAD enrolled from 61 practices
between July 1, 2010, and June 30, 2011. Within the
PINNACLE Registry, PAD was deﬁned by one of the
following self-identiﬁed criteria by patients: 1) claudication,
either with exertion or at rest; 2) amputation for arterial
vascular insufﬁciency; 3) vascular reconstruction, bypass
surgery, or percutaneous intervention to the extremities
(excluding dialysis ﬁstulas and vein stripping); 4) documented
aortic aneurysm with or without repair; or 5) positive
noninvasive test (e.g., ankle brachial index 0.9, ultrasound,
magnetic resonance, computed tomography) or diagnostic
angiographic stenosis of >50% in any major peripheral artery
(e.g., renal, subclavian, femoral, iliac). We excluded 2,945
patients from whom information on SES was missing
(zip code data were not available). Our ﬁnal study cohort
comprised 62,690 PAD patients from 61 sites. For the
analyses in this study, as patients may have had multiple
visits in the PINNACLE Registry, we used information
from the ﬁrst visit to represent each patient only once.
SES and processes of care. The key independent variable
was patients’ SES, which was deﬁned by the median income
of the patient’s zip code of residence. This approach to
categorize levels of socioeconomic status has been used in
previous reports of various disease conditions (25–27). The
primary study outcome was treatment with two secondary
preventive medications: an antiplatelet agent (aspirin or
clopidogrel) and a statin, both of which are Class I indica-
tions for PAD by the ACC/American Heart Association
(AHA) PAD guidelines and PAD performance measures
(28,29). Patients with documented contraindications to
antiplatelet therapy (e.g., history of gastrointestinal bleeding)
or statins were excluded from the analysis of each treatment.
Moreover, for the analyses of antiplatelet therapy, we further
excluded 9,295 patients already on warfarin therapy given
that warfarin may inﬂuence the use of antiplatelet therapy.
Statistical analysis. Patients were categorized into quintiles
of SES, with quintile 1 representing the lowest SES and
quintile 5 the highest. Baseline differences across quintiles of
SES were then compared using the Mantel-Haenszel trend
test for categorical variables and the linear trend test for
continuous variables.
Separate multivariable hierarchical modiﬁed Poison models
were used to assess the relationship between SES and treat-
ment with antiplatelet therapy and statins. We employed
two-level hierarchical models to adjust for clustering of
patients within practices, with individual practices mod-
eled as random effects and other patient characteristics
modeled as ﬁxed effects within each practice (30). This ap-
proach allowed us to control for measured and unmeasured
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53between-practice confounding, as the use of hierarchical
models ensured that patients with similar SESs were
compared with each other from the same practice.
To better understand the extent of the practice-site vari-
ation in accounting for treatment differences by SES, we
performed a 2-step sequential adjustment. First, we adjusted
for practice site only, to assess the extent to which differ-
ences by SES were attenuated. This step allowed us to
understand whether treatment differences by SES persisted
when patients of different SESs within the same site were
compared. Next, we additionally controlled for clinical char-
acteristics, including age, sex, insurance status, diabetes,
dyslipidemia, history of MI, history of revascularization in
the previous 12 months, history of congestive heart failure,
and history of stroke.
For each analysis, the null hypothesis was evaluated at a
2-sided signiﬁcance level of 0.05, with 95% conﬁdence
intervals (CIs) calculated using robust SEs. All analyses were
performed with SAS version 9.3 (SAS Institute, Cary,
North Carolina) and R version 2.10.0.Results
The baseline characteristics of the 62,690 PAD patients
by SES quintiles are summarized in Table 1. There was no
difference in baseline characteristics of patients among prac-
tices categorized by tertiles of mean patient income (Table 2).
The median number of patients per site was 151 (interquartile
range [IQR]: 16 to 1,328) patients per site. Patients in the
lowest SES quintile were from zip codes with median
household incomes of <$34,486 annually, while those in theTable 1 Baseline Demographic and Clinical Characteristics of the St
Characteristic
Socioeconom
Quintile 1
(n ¼ 12,521)
Quintile 2
(n ¼ 12,513)
Quintile
(n ¼ 12,5
Patient income, range,y US$ 4,583–34,486 34,486–41,117 41,118–50
Age, median (IQR), yrs 69.0
(61.0–78.0)
71.0
(62.0–79.0)
70.0
(62.0–7
Male, % 60.6 62.8 62.5
Insurance category,z n (%)
Private 54.5 63.3 59.7
Public 41.1 33.0 37.2
None 4.5 3.7 3.1
Comorbidity, n (%)
CAD 86.9 86.2 86.6
Dyslipidemia 77.2 80.8 82.1
Diabetes mellitus 33.4 34.0 32.2
Hypertension 82.3 85.2 84.4
Stroke or TIA 11.5 24.1 25.2
MI 30.9 29.9 31.8
CABG in previous 12 months 23.29 25.4 33.8
PCI in previous 12 months 47.0 48.8 43.0
*Continuous variables compared using linear trend test; categorical variables compared using Mantel-Ha
zPublic insurance refers to Medicare, Medicaid, military, and state insurance.
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; IQR ¼ interquartile range; MI ¼
USD ¼ US dollars.highest quintiles were from zip codes with annual median
household incomes of >$60,868.
The median age of the overall cohort was 70.0 (IQR:
62.0–78.0) years, and 62.4% were men. Nearly 60% of
patients had private insurance, and only 4.2% were unin-
sured. There were high prevalences of coronary artery disease
(85.4%), dyslipidemia (81.5%), and hypertension (83.3%) in
the cohort. Nearly one third of patients were diabetic and
one quarter were active smokers. Finally, 30.3% of patients
had undergone coronary artery bypass surgery, whereas
41.4% had undergone percutaneous coronary intervention
within the previous year.
Compared with patients in the highest SES quintiles,
patients in the lower SES quintiles were slightly younger,
more frequently female, and less likely to have private health
insurance. Patients in lower SES quintiles were also more
likely to have undergone percutaneous coronary intervention
in the previous year and to be active smokers, and were less
likely to have undergone coronary artery bypass surgery in
the previous year and to have had a prior stroke. Lastly, rates
of dyslipidemia, diabetes, hypertension, congestive heart
failure, and prior myocardial infarction were clinically similar
across quintiles.
Use of cardioprotective therapy. Treatment rates with sta-
tins decreased in a graded fashion going from higher to lower
SES: 85.8% in quintile 5 to 72.5% in quintile 1 (Table 3).
Compared with patients in the highest SES quintile, PAD
patients in the lowest SES quintile were 16% less likely to
be treated with statins (unadjusted rate ratio [RR]: 0.84;
95% CI: 0.83 to 0.86; p < 0.0001). Notably, sites with
higher mean incomes among its patients had greaterudy Cohort, Stratiﬁed by Socioeconomic Status
ic Status
All Patients
(N ¼ 62,690) p Value*
3
65)
Quintile 4
(n ¼ 12,511)
Quintile 5
(n ¼ 12,580)
,371 50,372–60,868 60,869–200,001 4,583–200,001 <0.001
8.0)
71.0
(63.0–79.0)
71.0
(63.0–79.0)
70.0
(62.0–78.0)
<0.001
61.7 64.2 62.4 <0.001
58.7 61.0 59.4 <0.001
37.9 35.2 36.9 <0.001
3.4 3.8 3.7 <0.001
83.6 83.5 85.4 <0.001
82.7 84.5 81.5 <0.001
31.5 32.2 32.7 <0.001
82.3 82.4 83.3 0.010
16.4 18.0 19.0 <0.001
28.7 31.5 30.6 0.982
33.2 35.8 30.3 <0.001
33.7 34.7 41.4 <0.001
enszel trend test. yCalculated as the median household income per year in each patient’s zip code.
myocardial infarction; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic attack;
Table 2
Baseline Demographic and Clinical Characteristics Within Practices, by Tertile of
Mean Patient Income
Characteristic
Mean Income
All Patients
(N ¼ 61) p Value*
Tertile 1
(n ¼ 20)
Tertile 2
(n ¼ 20)
Tertile 3
(n ¼ 21)
Age, yrs 68.7
(66.3–71.7)
71.1
(68.4–72.5)
70.6
(69.5–72.0)
70.3
(68.3–72.2)
0.16
Male, % 57.8
(53.1–62.9)
62.8
(55.4–69.1)
60.6
(55.4–65.2)
60.6
(55.4–66.1)
0.81
Insurance category,y %
Private 46.9
(26.0–69.4)
45.6
(34.5–74.9)
44.8
(24.7–68.2)
45.5
(25.0–72.9)
0.69
Public 50.0
(23.7–69.3)
32.8
(21.3–65.1)
47.1
(28.4–68.8)
45.9
(23.0–68.8)
0.48
None 2.9
(0.0–9.7)
2.4
(0.9–7.6)
3.3
(1.0–5.9)
2.6
(0.8–7.5)
0.47
Comorbidity, n (%)
CAD 84.9
(70.5–95.8)
83.9
(76.6–98.4)
77.3
(60.4–91.1)
83.2
(70.0–94.6)
0.05
Dyslipidemia 75.0
(60.4–88.7)
86.4
(74.2–92.3)
78.8
(74.9–92.0)
79.8
(71.4–90.9)
0.17
Diabetes mellitus 40.0
(30.7–50.0)
30.3
(17.4–37.5)
33.9
(29.2–41.4)
33.9
(27.0–43.6)
0.58
Hypertension 90.2
(78.4–100)
87.6
(75.8–98.3)
82.1
(78.4–92.1)
85.3
(78.3–97.0)
0.19
Stroke or TIA 7.8
(2.7–11.7)
7.0
(1.6–11.8)
7.0
(3.6–9.0)
7.2
(3.1–11.0)
0.88
MI 27.1
(9.6–51.7)
22.4
(10.6–39.2)
26.0
(11.2–30.4)
26.0
(10.0–40.0)
0.14
CABG in previous
12 months
8.0
(4.4–21.7)
2.4
(0.021.4)
12.4
(1.5–31.4)
6.8
(1.2–29.1)
0.56
PCI in previous
12 months
24.3
(8.3–50.0)
14.3
(3.4–51.4)
18.8
(7.2–47.2)
19.3
(7.1–50.0)
0.92
Values are median (IQR). *Continuous variables compared using linear trend test; categorical variables compared using Mantel-Haenszel trend test.
yPublic insurance refers to Medicare, Medicaid, military, and state insurance.
Abbreviations as in Table 1.
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54percentages of patients prescribed a statin medication
(weighted correlation coefﬁcient: 0.48) (Fig. 1). After
adjustment for the practice at which a patient received care,
treatment differences by SES were markedly attenuated
(adjusted RR for quintile 1 vs. 5: 0.97; 95% CI: 0.97 to 0.99;
p ¼ 0.003). Further adjustment for clinical variables was
associated with only a small attenuation of differences by SES
(fully adjusted RR: 1.00; 95% CI: 0.99 to 1.01; p ¼ 0.772).
A similar pattern was observed for quintiles 2, 3, and 4
(Table 4).
Rates of any antiplatelet treatment were lowest among
those in quintile 1 (79.0%, vs 84.6% in quintile 5) (Table 3).
Compared with patients in the highest SES quintile,Table 3 Medication* Treatment Rates, Stratiﬁed by Socioeconomic
Medication
Socioe
Quintile 1
(n ¼ 12,521)
Quintile 2
(n ¼ 12,513)
Q
(n
Any antiplatelet: clopidogrel and/or aspirin 79.0 83.0
Statin 72.5 77.6
*Medications described among those eligible (without contraindication). yStratiﬁed by range of patient in
follows: quintile 1 ¼ 4,583–34,486; quintile 2 ¼ 34,486–41,117; quintile 3 ¼ 41,118–50,371; quintile 4
trend test; categorical variables compared using Mantel-Haenszel trend test unless otherwise noted.
KW ¼ Kruskal-Wallis test; other abbreviations as in Table 1.patients in the lowest SES quintile were 7% less likely to be
treated with any antiplatelet medication (unadjusted RR:
0.93; 95% CI: 0.91 to 0.94; p < 0.0001). As with statin
treatment, sites with a higher median income among its
patients had greater percentages of patients prescribed an
antiplatelet agent (weighted correlation coefﬁcient: 0.30)
(Fig. 2). After adjustment for the practice at which a patient
received care, treatment differences by SES were nearly
eliminated (adjusted RR: 0.98; 95% CI: 0.97 to 1.00;
p ¼ 0.012). Further adjustment for the clinical characteris-
tics of patients had minimal effect on attenuation of effect
between the quintiles of SES (fully adjusted RR: 1.00; 95%
CI: 0.99 to 1.01; p ¼ 0.878) (Table 4).Statusy
conomic Status
All Patients
(N ¼ 62,690) p Valuez
uintile 3
¼ 12,565)
Quintile 4
(n ¼ 12,511)
Quintile 5
(n ¼ 12,580)
84.8 83.1 84.6 82.9 <0.001
83.2 81.5 85.8 80.1 <0.001
come (in USD) (calculated as the median household income per year in each patient’s zip code), as
¼ 50,372–60,868; and quintile 5 ¼ 60,869–200,001. zContinuous variables compared using linear
30000 40000 50000 60000 70000
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Figure 1 Correlation Between SES and Statin Treatment Rates
The size of circles is a weighted representation of the number of patients with
peripheral artery disease (PAD) at a practice. SES ¼ socioeconomic status,
deﬁned by the median income of each patient’s zip code.
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Figure 2
Correlation Between SES and Antiplatelet
Treatment Rates
The size of circles is a weighted representation of the number of patients with PAD
at a practice. Abbreviations as in Figure 1.
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55Discussion
Among outpatients with PAD, we found that treatment
with antiplatelet and statin therapies differed by SES. These
differences, however, were largely explained by the clinical
practice at which patients received care. Our ﬁndings suggestTable 4 Association of Socioeconomic Status* With PAD Treatment
Treatment/Quintile
Unadjusted
RR
(95% CI) p Value
Statin therapy
Quintile 5 [Reference] – [R
Quintile 4 0.95
(0.94–0.96)
<0.001
(
Quintile 3 0.97
(0.96–0.98)
<0.001
(
Quintile 2 0.90
(0.89–0.91)
<0.001
(
Quintile 1 0.84
(0.83–0.86)
<0.001
(
Any antiplateletz
Quintile 5 [Reference] – [R
Quintile 4 0.99
(0.98–1.00)
0.022
(
Quintile 3 1.00
(0.99–1.01)
0.946
(
Quintile 2 0.98
(0.97–0.99)
<0.0001
(
Quintile 1 0.93
(0.91–0.94)
<0.0001
(
*Stratiﬁed by range of patient income (in USD) (calculated as the median household income per year
quintile 3 ¼ 41,118–50,371; quintile 4 ¼ 50,372–60,868; and quintile 5 ¼ 60,869–200,001. yClinical ch
revascularization in the previous 12 months, insurance, congestive heart failure, diabetes, stroke, dyslip
CI ¼ conﬁdence interval; PAD ¼ peripheral artery disease; RR ¼ relative risk.that initiatives to reduce disparities in medication treatment
for PAD should target practices with high proportions of
low-SES patients.
Studies from different populations have demonstrated that
cardiovascular risk factors and disease disproportionately
affect those of lower SES (31–36), and among patients withAdjusted for Practice Site
Further Adjusted
for Clinical Characteristicsy
RR
(95% CI) p Value
RR
(95% CI) p Value
eference] – [Reference] –
0.98
0.97–1.00)
0.0134 0.98
(0.97–1.00)
0.007
0.98
0.97–1.00)
0.0124 0.99
(0.98–1.00)
0.172
0.98
0.95–1.00)
0.0341 0.99
(0.97–1.01)
0.327
0.97
0.95–0.99)
0.0029 1.00
(0.99–1.01)
0.772
eference] – [Reference] –
1.00
0.99–1.01)
0.556 1.01
(1.00–1.01)
0.237
0.99
0.98–1.01)
0.347 1.00
(0.99–1.01)
0.788
1.00
0.99–1.01)
0.794 1.01
(1.00–1.02)
0.071
0.98
0.97–1.00)
0.012 1.00
(0.99–1.01)
0.878
in each patient’s zip code), as follows: quintile 1 ¼ 4,583–34,486; quintile 2 ¼ 34,486–41,117;
aracteristics adjusted model: model adjusted for practice, age, sex, history of myocardial infarction,
idemia, and tobacco use. zExcluding patients on warfarin.
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56cardiac disease, those with lower SES experience higher
morbidity and mortality (4,37–40). Patient-level risk factors,
such as increased health-risk behaviors, may account for
some of the increased morbidity and mortality seen in
patients of low SES (4,41). However, identifying factors
beyond patient risk factors and behaviors (36), which are not
easily modiﬁable, is crucial to quality initiatives that address
the Institute of Medicine mandates to improve outcomes
and reduce disparities. For instance, several studies have re-
ported variation in compliance with evidence-based therapies
for other cardiac conditions by SES, and may partly explain
the association between lower SES and worse outcomes
(37,42,43). However, these prior studies have not examined
differences in treatments of PAD by SES. Moreover, they
have not examined the extent to which the site at which
a patient receives his or her care inﬂuences treatment rates.
The present study expands on ﬁndings of other disparities
research and focuses on PAD, in which outcomes research
has been limited. Prior studies of disparities in PAD have
focused on rates of utilization of lower extremity revascu-
larization by SES or reported rates of optimal medical
therapy by insurance status (5–9). This present study con-
ﬁrms ﬁndings similar to those in other cardiac disease states,
in that the use of secondary preventive treatments for PAD
was lower among those of low SES. This ﬁnding highlights
an important gap in the quality of care of patients with
PAD, especially because the cost of aspirin and generic
statins is low and should not pose signiﬁcant barriers to
patient access to these evidence-based therapies.
The present analysis further contributes to disparities
research by highlighting the central role of the practice at
which patients receive their care in explaining treatment
differences by SES. We found that disparities in medication
use between the highest and lowest SESs were markedly
attenuated after adjustment for site-level variation; this
ﬁnding suggests that differences in medication use were
predominately explained by differences in sites that largely
treat patients of low SES compared with sites caring for
largely higher-SES patients. We believe these ﬁndings serve
as an important paradigm for future efforts to reduce dis-
parities in care, which will need to target clinical practices as
intervention units and go beyond patient-level interventions.
For PAD, future studies are needed to determine whether
system-wide improvements at the practice level (e.g., iden-
tiﬁcation of patients with PAD, initiation of secondary
prevention medications, and physician education) or
resource interventions at practices with high proportions of
low-SES patients (e.g., electronic medical systems, decision
aids) will reduce disparities in treatment by SES. Quality-
improvement initiatives that provide feedback to sites by
providing reports benchmarking performance of the site in
relation to pre-speciﬁed goals or national averages for select
performance metrics may help change behavior at a site.
Study limitations. First, we relied on patient diagnoses for
PAD, which were self-reported by practices. It is possible
that some patients were not classiﬁed as having PAD;however, we believe any misclassiﬁcation would have been
nondifferential and are unlikely to have inﬂuenced our ﬁnd-
ings. Moreover, we were unable to examine severity of PAD,
as we did not have physiological (e.g., ankle-brachial index) or
angiographic data on all patients. Similarly, we were unable to
analyze the variability in use of medication by the speciﬁc
PAD diagnosis (i.e., surgery vs. noninvasive test) Second, we
deﬁned SES by median income in each patient’s residential
zip code, which is a common strategy in previous studies (25–
27), and did not examine other socioeconomic variables, such
as educational level, which were not available in the
PINNACLE registry. Third, our study was conducted among
cardiology practices participating in PINNACLE, a quality-
improvement registry; therefore, treatment rates by SES
may differ in nonparticipating practices, including primary
care centers. Given voluntary enrollment in this quality-
improvement initiative, it is possible that the rates of medi-
cation use are higher than expected in nonparticipating sites.
We did not adjust for race in the clinical model given that it
was frequently missing (nearly 50% of patients had missing
data on this variable); however, most of the variation in
treatment between the SES groups could be accounted for by
practice-level variation. Furthermore, although it is possible
that the differences in therapies by SES could be mediated by
some, but not all, physicians within a practice, the current
PINNACLE registry does not provide information on
provider characteristics sufﬁcient to allow us to currently
examine this possibility. Regardless, further education and
resources geared at practices with high proportions of low-SES
patients have the potential to improve compliance to therapies
indicated for PAD. Finally, we were unable to examine
longitudinal outcomes in this study.
Conclusions
Among patients with PAD, treatment with evidence-based
antiplatelet and statin therapies differed by patients’ SES.
These differences, however, were largely explained by the
clinical practice at which patients received care, suggesting
variation in treatment patterns across centers. Future efforts to
reduce treatment disparities by SES in PAD and to improve
outcomes in these vulnerable populations should target
practices serving high proportions of patients of low SES.
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